REVIEW

Brain renin–angiotensin system dysfunction in hypertension: recent advances and perspectives

¹Shereeni J. Veerasingham & ^{*,1}Mohan K. Raizada¹Department of Physiology and Functional Genomics, University of Florida, U.S.A.

This review focuses on the dysfunction of the intrinsic brain renin–angiotensin system (RAS) in the pathogenesis of hypertension. Hyperactivity of the brain RAS plays a critical role in mediating hypertension in both humans and animal models of hypertension, including the spontaneously hypertensive rat (SHR). The specific mechanisms by which increased brain RAS activity results in hypertension are not well understood but include increases in sympathetic vasomotor tone and impaired arterial baroreflex function. We discuss the contribution of endogenous angiotensin (Ang) II actions on presympathetic vasomotor rostral ventrolateral medulla neurons to enhance sympathetic activity and maintain hypertension. In addition, we discuss Ang II-induced attenuation of afferent baroreceptor feedback within the nucleus tractus solitarius and its relevance to the development of hypertension. We also outline the cellular and molecular mechanisms of Ang II signal transduction that may be critical for the initiation and establishment of hypertension. In particular, we present evidence for a phosphoinositide-3-kinase-dependent signaling pathway that appears to contribute to hypertension in the SHR, possibly via augmented Ang II-induced increases in neuronal firing rate and enhanced transcriptional noradrenaline neuromodulation. Finally, we outline future directions in utilizing our understanding of the brain RAS dysfunction in hypertension for the development of improved therapeutic intervention in hypertension.

British Journal of Pharmacology (2003) **139**, 191–202. doi:10.1038/sj.bjp.0705262

Keywords: Brain renin–angiotensin system; angiotensin receptor signal transduction; spontaneously hypertensive rat; sympathetic activity; Baroreflex; phosphoinositide-3-kinase; noradrenaline neuromodulation

Abbreviations: ACE, angiotensin converting enzyme; Ang, angiotensin; AP1, activating protein 1; AT₁ and AT₂, angiotensin type 1 and type 2; BP, blood pressure; CaMKII, calcium/calmodulin-dependent protein kinase II; D-βH, dopamine β-hydroxylase; DOCA, deoxycorticosterone acetate; FRK, Fos-regulating kinase; I_A, transient A type K⁺ current; i.c.v., intracerebroventricular; I_{Kv}, delayed rectifier K⁺ current; JNK, c-Jun NH₂-terminal kinase; MAP, mitogen-activated protein; MnPO, median preoptic nucleus; NA, noradrenaline; NAT, noradrenaline transporter; NTS, nucleus tractus solitarius; PI, phosphoinositide; PI3K, phosphoinositide-3-kinase; PKB and PKC, protein kinase B and C; PLC, phospholipase C; PVN, paraventricular nucleus; RAS, renin–angiotensin system; SFO, subfornical organ; SHR, spontaneously hypertensive rat(s); TGR mRen2, renin transgenic rat(s); TH, tyrosine hydroxylase

Introduction

Essential hypertension is one of the most prevalent cardiovascular disorders, afflicting approximately 15% of the population. It is a major risk factor for other cardiovascular diseases such as peripheral vascular disease and ischemic heart disease, as well as stroke and end-stage renal disease, thereby resulting in considerable morbidity and mortality. The etiology of this disease is multifactorial, resulting from the interaction of a number of genetic and environmental factors. Despite decades of research efforts, the specific mechanisms involved in mediating the elevation in blood pressure (BP) that characterizes hypertension are poorly understood. BP is regulated by sympathetic and parasympathetic nerve activity, circulating hormones and local autoregulatory mechanisms that interact to control cardiac output and vascular resistance. In addition, BP is modulated by the central integration of afferent

neural and humoral inputs from the periphery. An increasing number of studies have demonstrated a critical role for the central nervous system in the development and maintenance of hypertension. In particular, increases in sympathetic nerve activity and alterations in arterial baroreflex function appear to contribute to the pathogenesis of this disease.

The development of hypertension in various animal models of hypertension, such as the spontaneously hypertensive rat (SHR), the renin transgenic (TGR mRen2) rat, the Dahl salt-sensitive rat and the deoxycorticosterone acetate (DOCA)-salt rat, is associated with increases in sympathetic activity (Takeda & Bunag, 1980; Arribas *et al.*, 1996; Cabassi *et al.*, 2002; Leenen *et al.*, 2002). Increased sympathetic nerve activity would cause an elevation in BP via a direct vasoconstriction, and by increasing the force and rate of contraction of the heart. In addition, renal sympathetic nerve activity causes renin secretion that activates the systemic renin–angiotensin system (RAS) leading to angiotensin (Ang) II-induced vasoconstriction and antinatriuresis. Sustained increases in

*Author for correspondence at: Department of Physiology and Functional Genomics, College of Medicine, University of Florida, PO Box 100274, Gainesville, FL 32610, U.S.A.;
E-mail: mraizada@phys.med.ufl.edu

sympathetic outflow would also contribute to elevation of BP by causing trophic effects on vascular smooth muscle leading to increases in vascular resistance and enhanced responses to vasoconstrictor stimuli.

Alteration in arterial baroreflex function has also been implicated in the development of hypertension. The arterial baroreflex responds to changes in BP detected by carotid sinus and aortic arch baroreceptors, by modulating parasympathetic and sympathetic nerve activity and, hence, heart rate and vascular tone. This minimizes fluctuations in BP and maintains it close to a particular set point. In response to a static increase in BP, the baroreflex rapidly resets towards a higher pressure (Andresen & Yang, 1989). In hypertensive conditions, resetting of the operational point of the arterial baroreflex may therefore contribute to maintaining an increased BP rather than opposing it. In SHR, Lyon hypertensive rats, TGR mRen2 rats, DOCA-salt rats and Dahl salt-sensitive rats, the gain of the baroreflex, a measure of the baroreceptor reflex sensitivity, is decreased compared to normotensive controls resulting in blunted baroreflex control of heart rate and sympathetic nerve activity (Miyajima & Bunag, 1986; Hayashi *et al.*, 1988; Nakamura *et al.*, 1988; Lantelme *et al.*, 1998; Borgonio *et al.*, 2001). In many of these models, the impairment in baroreflex function precedes the development of hypertension and may therefore contribute to the development and maintenance of hypertension.

Similar to animal models of hypertension, primary human hypertension is also associated with increases in sympathetic activity and blunted arterial baroreflexes. Patients in the early phase of hypertension exhibit elevated plasma noradrenaline (NA) levels (Goldstein, 1981) and increased cardiac and renal NA spillover (Esler *et al.*, 1988). While noncentral mechanisms such as facilitation of NA release (Floras, 1992) and impairment of neuronal NA reuptake (Rumantir *et al.*, 2000) contribute to increased NA spillover, centrally mediated increases in sympathetic nerve outflow appear to play an important role. Microneurograph recordings of the peroneal nerve (Anderson *et al.*, 1989; Grassi *et al.*, 1998) and single-unit recordings (Grassi *et al.*, 1998) in hypertensive patients indicate increased sympathetic nerve discharge, supporting the concept of a central neural mechanism for sympathetic activation in hypertension. In addition, in untreated hypertensive patients, spectral analysis of heart rate variability reveals an enhanced low-frequency component (0.1 Hz), which is considered a marker of sympathetic activity (Guzzetti *et al.*, 1988). Furthermore, the efficacy of centrally acting antihypertensive agents such as clonidine also implicates a central mechanism in primary human hypertension. In both borderline hypertensives and hypertensive patients, the baroreflex control of heart rate and muscle sympathetic nerve activity is blunted and the gain of the baroreflex is decreased (Matsukawa *et al.*, 1991a,b). While these studies implicate central mechanisms of sympathetic activation in the pathogenesis of hypertension, particular areas/nuclei involved are yet to be identified.

In hypertensive animals, functional changes within the central nervous system have been detected largely in hypothalamic and medullary areas that modulate sympathetic outflow (Colombari *et al.*, 2001; De Wardener, 2001). A large number of neurotransmitters and neuromodulators contribute to regulating sympathetic outflow. Our research efforts have

focused on a neuropeptide, Ang II, as increased expression and activity of components of the intrinsic brain RAS play a key role in many forms of experimental hypertension including the SHR, the TGR mRen2 rat, the Dahl salt-sensitive rat, the DOCA-salt rat and renal hypertensive rats (Itaya *et al.*, 1986; Berecek *et al.*, 1987; Huang & Leenen, 1998; Fontes *et al.*, 2000; De Wardener, 2001; Kagiya *et al.*, 2001; Park & Leenen, 2001). Some of these models, including the SHR, exhibit both a hyperactive endocrine RAS, characterized by elevated circulating Ang II, as well as a hyperactive tissue RAS, characterized by elevated tissue Ang II. Within the brain, Ang II contributes to cardiovascular regulation *via* its action at various hypothalamic and medullary areas to enhance sympathetic outflow, blunt the sensitivity of the baroreflex and stimulate secretion of vasopressin (Culman *et al.*, 1995; Averill & Diz, 2000; McKinley *et al.*, 2001; Dampney *et al.*, 2002). This article provides a brief overview of the brain RAS with emphasis on recent developments in this field. We then critically review recent studies that have advanced our understanding of the dysfunction of the brain RAS that underlies altered central BP regulation during the development and maintenance of hypertension. We will also discuss the cellular and molecular basis of Ang II signal transduction that may contribute to hypertension. Finally, we outline future directions that one must consider in advancing the field of central BP regulation from the experimental to the therapeutic level.

Altered regulation of the brain RAS in hypertension

Overview of the brain RAS

The RAS is an enzymatic cascade by which angiotensinogen is cleaved by renin and then by angiotensin converting enzyme (ACE) to produce Ang II, and subsequently cleaved by aminopeptidases to form other Angs. The brain expresses genes that encode all components of the RAS including angiotensin type I (AT₁) and type II (AT₂) receptors (Lenkei *et al.*, 1997; Phillips & Sumners, 1998). A notable difference between the brain RAS and the systemic RAS is that the renin transcript predominantly expressed in the brain contains an alternate first exon (Lee-Kirsch *et al.*, 1999; Clausmeyer *et al.*, 2000; Sinn & Sigmund, 2000). This transcript encodes a truncated renin isoform that is predicted to be intracellular as it lacks the prefragment that targets to the secretory pathway. Recently, a receptor for prorenin/renin that appears to increase the efficiency of angiotensinogen cleavage to Ang I has been identified (Nguyen *et al.*, 2002). It is highly expressed in tissues in which an intrinsic RAS has been described, including the brain, and may play an important physiological role in these tissues where angiotensinogen and renin concentrations are much lower than in plasma. Although Ang II actions are the best characterized, a role for Ang III (Ang 2–8) in cardiovascular regulation is emerging and it has been suggested that conversion of Ang II to Ang III is required for central Ang II actions (Reaux *et al.*, 2001). Irrespective of the ligand (Ang II or Ang III), almost all the central actions on BP regulation and fluid homeostasis are mediated by the AT₁ receptor (Llorens-Cortes & Mendelsohn, 2002). Accordingly, within the brain, high densities of the AT₁ receptor are

distributed in cardiovascular regulatory areas including the lamina terminalis, that is, the subfornical organ (SFO), median preoptic nucleus (MnPO) and organum vasculosum laminae terminalis, the paraventricular nucleus (PVN), lateral parabrachial nucleus, ventrolateral medulla and the nucleus tractus solitarius (NTS) (Obermuller *et al.*, 1991; Tsutsumi & Saveedra, 1991; Phillips *et al.*, 1993; Allen *et al.*, 1999). In humans, a single gene on chromosome 3 encodes the AT₁ receptor (Curnow *et al.*, 1992) whereas two AT₁ receptor subtypes, AT_{1A} and AT_{1B}, encoded by distinct genes on different chromosomes have been identified in rodents (Murphy *et al.*, 1991; Elton *et al.*, 1992; Sandberg *et al.*, 1992; Sasamura *et al.*, 1992; Lewis *et al.*, 1993). The AT_{1A} receptor is the predominantly expressed subtype in central cardiovascular regulatory areas in rodents (Lenkei *et al.*, 1995), contributes to maintaining resting BP, and mediates pressor responses to central administration of Ang II (Davisson *et al.*, 2000; Li *et al.*, 2003). Although the AT₂ receptor is moderately expressed in certain nuclei involved in cardiovascular regulation such as the locus coeruleus, lateral septum and the medial amygdala (Song *et al.*, 1992; Lenkei *et al.*, 1997), its contribution to BP regulation in these areas remains elusive. However, functional evidence implicates a role for an AT₂ receptor-mediated contribution to baroreflex regulation (Lin *et al.*, 1997; 2001; Luoh & Chan, 1998). Vasopressin release elicited by central administration of Ang II is mediated mainly by AT₁ receptors, but is also mediated by AT₂ receptors (Hogarty *et al.*, 1992; Veltmar *et al.*, 1992). An increase in endogenous Ang III also causes vasopressin release but the receptor that mediates this effect has not yet been identified (Zini *et al.*, 1996). A receptor that is pharmacologically distinct from either AT₁ or AT₂ receptors appears to mediate Ang 1–7 actions on BP regulation, which in most cases oppose Ang II actions (Fontes *et al.*, 1994; Couto *et al.*, 2002). Thus, the broad function of the brain RAS in cardiovascular regulation is fairly well understood but its contribution to BP regulation in different areas/nuclei, and its altered regulation in hypertension is still a focus of much investigation.

Dysfunction of the brain RAS is implicated in the development of hypertension

The SHR has been the most widely used animal model for investigation of brain RAS dysfunction in hypertension. Increases in brain angiotensinogen expression precede the development of hypertension in SHR (Tamura *et al.*, 1996), especially in the preoptic area where increases in angiotensinogen were apparent in 4-week-old SHR and increased with age (Shibata *et al.*, 1993). In addition, renin-like activity in the anterior hypothalamus and NTS was higher in SHR compared to WKY rats during the development of hypertension (Ruiz *et al.*, 1990). Ang II content and turnover within the hypothalamus, and Ang II immunoreactivity within the PVN and supraoptic nucleus, is also increased in adult SHR compared to their normotensive WKY control rats (Weyhenmeyer & Phillips, 1982; Ganten *et al.*, 1983; Hermann *et al.*, 1984; Phillips & Kimura, 1988). SHR also exhibit increased density of Ang II binding sites within the MnPO, SFO, PVN and NTS, and AT_{1A} receptor mRNA within the preoptic area compared to WKY rats (Gutkind *et al.*, 1988; Komatus *et al.*, 1996). Furthermore, a recent study

demonstrated increased cellular AT₁ receptor density within the RVLM in SHR *versus* WKY rats (Hu *et al.*, 2002). Pressor responses to intracerebroventricular (i.c.v.) injection of Ang II, or microinjections of Ang II within the preoptic area, NTS and RVLM, and depressor effects within the CVLM, are also correspondingly greater in SHR *versus* WKY rats, indicating increased receptor density and/or sensitivity in the SHR (Casto & Phillips, 1985; Matsuda *et al.*, 1987; Wright *et al.*, 1987; Muratani *et al.*, 1991; Zhu *et al.*, 1998). Thus, it can be concluded from these studies that a hyperactivity of the brain RAS precedes and/or parallels the development of hypertension in the SHR.

Studies utilizing pharmacological agents have provided evidence that the hyperactivity of the brain RAS mediates hypertension. Blockade of activity of the brain RAS utilizing injections of ACE inhibitors such as captopril, or an AT₁ receptor antagonist, losartan, into the lateral ventricle, decreases BP in SHR and TGR mRen2 rats as well as other models of hypertension, but does not affect BP in their normotensive controls (Hutchinson *et al.*, 1980; Faber & Brody, 1984; Itaya *et al.*, 1986; Berecek *et al.*, 1987; Teruya *et al.*, 1995; Szczepanska-Sadowska *et al.*, 1998; Park & Leenen, 2001). Furthermore, microinjections of losartan into the anterior hypothalamic area also result in a decrease in BP in SHR (Yang *et al.*, 1992). The depressor effect following inhibition of brain RAS activity in hypertensive rats appears to be mainly due to a decrease in sympathetic activity (Berecek *et al.*, 1987; Huang & Leenen, 1998). These studies indicate that a hyperactivity of the brain RAS mediates hypertension in SHR and other hypertensive models. The role of the brain RAS in maintaining BP in normotensive rats is less clear as there are discrepancies in the literature, with some reports suggesting a tonic role for Ang peptides in maintaining resting BP (Ito & Sved, 1996; Tagawa *et al.*, 1999; Fontes *et al.*, 2000).

Antisense gene targeting of components of the RAS within the brain has provided further support for the view that a hyperactive brain RAS mediates hypertension. Inhibition of brain RAS activity by i.c.v. administration of antisense oligonucleotides to angiotensinogen or AT₁ receptor mRNA resulted in a short-term decrease in BP in SHR, whereas it had no effect in WKY rats (Wielbo *et al.*, 1995; Kagiya *et al.*, 1999). Adeno-associated virus vector-mediated delivery of AT₁ receptor antisense oligonucleotides, either i.c.v. or directly into the hypothalamus, extended the magnitude and duration of the depressor effect up to 9 weeks in SHR (Phillips *et al.*, 1997). In addition, cross-breeding of transgenic rats that exhibit decreased glial angiotensinogen concentrations with TGR mRen2 rats results in a marked reduction in brain Ang content and BP possibly via a vasopressinergic mechanism (Schinke *et al.*, 1999). Although studies employing PVN lesions or GABAergic blockade have implicated this nucleus in mediating hypertension via sympathetic activation (Ciriello *et al.*, 1984; Takeda *et al.*, 1991; Allen, 2002), antisense oligonucleotide inhibition of angiotensinogen mRNA within the PVN did not affect BP in SHR up to 24 h after injection despite decreased plasma catecholamine and vasopressin levels (Kagiya *et al.*, 1999). This suggests that Ang II within the PVN contributes to maintaining resting sympathetic activity and vasopressin release consistent with inhibition of Ang II effects mediated by parvocellular and magnocellular subdivisions of the PVN, but does not contribute significantly to maintaining hypertension in adult SHR. In TGR mRen2 rats,

AT₁ receptor antisense oligonucleotide administration into the PVN did not significantly alter BP, but abolished salt-induced exacerbation of hypertension in these rats (Li *et al.*, 1996). Overall, these findings have confirmed that hyperactivity of the brain RAS contributes to maintaining hypertension. Overactivity of the RAS within the PVN alone does not account for this effect but contributes to salt-induced exacerbation of hypertension.

Studies employing gene transfer or transgenic techniques to overexpress RAS components in a tissue-specific or cell type-specific manner in normotensive rats or mice have provided further insight into brain RAS dysfunction in hypertension, and a means to distinguish the functional contributions of the brain RAS from those of the systemic RAS. In normotensive rats, brain-specific *in vivo* gene transfer of the human ACE gene utilizing the hemagglutinating virus of Japan complexed with liposomes led to the widespread distribution of the transgene including expression in hypothalamic nuclei and in the ventral medulla (Nakamura *et al.*, 1999). These rats exhibited elevated central Ang II levels and developed hypertension. In mice, overexpression of both the human angiotensinogen and the human renin genes under the control of either a glial fibrillary acidic protein promoter or a synapsin I promoter resulted in glia- or neuron-specific expression of the transgenes respectively (Morimoto *et al.*, 2002). Both glia- and neuron-targeted double transgenic mice developed moderate hypertension, indicating that increased conversion of angiotensinogen to its active peptides within either glia or neurons results in hypertension. In the glia-targeted transgenic mice, AT₁ receptor activation and sympathetic activity but not vasopressin mechanisms mediated the hypertensive effect. Neuron-specific overexpression of the AT_{1A} receptor driven by a neuron-specific enolase promoter resulted in expression of the AT_{1A} transgene in neurons within cardiovascular as well as noncardiovascular regulatory areas in the brain with lower levels of expression in the adrenal medulla (Lazartigues *et al.*, 2002). Resting BP was normal in the AT_{1A} transgenic mice, indicating that an increase in AT_{1A} receptors by itself does not result in hypertension. In these transgenic mice, central AT₁ receptor blockade decreased BP whereas it did not affect BP in nontransgenic mice, indicating that AT₁ receptors contribute to resting BP only in mice with overexpression of AT_{1A} receptors. This study therefore suggests that an increase in the production of Ang II is required for the development of hypertension. Alternatively, effective baroreceptor buffering may prevent the development of hypertension in the AT_{1A} transgenic mice. While these studies were able to limit expression of the transgene to a particular cell type within the CNS, further studies that limit transgene expression to particular areas/nuclei would be required to dissect the contribution of the brain RAS in different cardiovascular regulatory areas in the development of hypertension.

The precise mechanisms by which increased brain RAS activity results in hypertension is not yet known, but appear to involve increased sympathetic vasomotor tone. AT₁ receptors are associated with presympathetic vasomotor neurons in the RVLM (Dampney *et al.*, 2002), the major source of excitatory supraspinal input to sympathetic preganglionic neurons in the intermediolateral cell column of the spinal cord. Bilateral microinjections of nonselective peptide Ang II receptor antagonists, (Sar¹, Thr⁸)Ang II (sarthran) or (Sar¹, Ile⁸)Ang

II (sarile), into the RVLM result in profound decreases in sympathetic nerve activity and BP in normotensive rats (Ito & Sved, 1996; Tagawa *et al.*, 1999). However, Lin *et al.* (1997, 2001) did not observe a decrease in BP in response to sarile microinjections into the RVLM for reasons that are unclear but may relate to differences in experimental conditions. Similar to findings in normotensive rats, microinjections of sarthran in SHR decreased BP to levels expected with total autonomic blockade (Ito *et al.*, 2002). The depressor effect of sarthran does not appear to be mediated by AT₁, AT₂ or Ang 1–7 receptors (Hirooka *et al.*, 1997; Ito & Sved, 2000; Potts *et al.*, 2000), raising questions regarding the endogenous ligand and receptor(s) that mediate this action. In anesthetized normotensive rats, AT₁ receptor blockade within the RVLM does not significantly alter sympathetic nerve activity or BP (Averill *et al.*, 1994; Fontes *et al.*, 1994; Potts *et al.*, 2000). However, a minor role for AT₁ receptors in contributing to resting activity of RVLM neurons is unmasked following blockade of tonic GABAergic inhibition (Tagawa *et al.*, 2000). In contrast, in anesthetized SHR, bilateral RVLM microinjections of an AT₁ receptor antagonist, candesartan, resulted in large decreases in BP and sympathetic nerve activity that were not observed in their normotensive controls (Allen, 2001). A similar decrease in BP was elicited by microinjections of valsartan, another AT₁ receptor antagonist, into the RVLM in SHR, but not WKY rats (Ito *et al.*, 2002). Furthermore, in conscious TGR mRen2 rats, bilateral RVLM microinjections of an AT₁ receptor antagonist resulted in a decrease in BP (Fontes *et al.*, 2000). Thus, in contrast to normotensive rats, AT₁ receptor stimulation within the RVLM contributes to the enhanced tonic sympathoexcitatory activity of RVLM vasomotor neurons in hypertensive rats. This finding is consistent with a study that demonstrated an upregulation of AT₁ receptors within the RVLM in SHR (Hu *et al.*, 2002). The input to AT₁ receptors in the RVLM appears to be from the PVN as disinhibition of the PVN resulted in an augmented decrease in BP in SHR compared to WKY rats, and this effect was eliminated by AT₁ receptor blockade within the RVLM (Ito *et al.*, 2002). In SHR, RVLM vasomotor neurons are subject to decreased tonic GABAergic inhibition and enhanced excitatory amino-acid input compared to normotensive controls (Smith & Barron, 1990; Ito *et al.*, 2000). Combined blockade of RVLM ionotropic excitatory amino-acid receptors and AT₁ receptors in SHR resulted in an additive effect (Ito *et al.*, 2002), suggesting actions via independent mechanisms. Alternatively, a single mechanism that augments both excitatory amino-acid input and AT₁ receptor stimulation of RVLM neurons and results in sympathoexcitation and hypertension cannot be ruled out.

There is functional evidence for the presence of Ang 1–7 receptors in the RVLM as RVLM microinjections of Ang 1–7 increase BP (Fontes *et al.*, 1994). Conversely, blockade of endogenous Ang 1–7 actions within the RVLM resulted in a decrease in BP in both anesthetized and conscious normotensive rats, suggesting a role for Ang 1–7 in maintaining BP (Fontes *et al.*, 1994; 1997). In conscious TGR mRen2 rats, RVLM microinjections of an Ang 1–7 antagonist resulted in augmented decreases in BP compared to normotensive rats (Fontes *et al.*, 2000). Thus, in TGR mRen2 rats, endogenous Ang 1–7 actions within the RVLM contribute to maintaining hypertension.

Increased brain RAS activity may also contribute to alterations in baroreflex function. Afferent baroreceptor input to the NTS inhibits sympathetic activity via a multisynaptic pathway involving an excitatory projection from the NTS to the CVLM, a subsequent inhibitory projection to the RVLM, and, lastly, an excitatory projection from the RVLM to sympathetic preganglionic neurons in the IML. Blockade of central AT₁ receptors utilizing i.c.v. infusions of losartan facilitated baroreflex control of heart rate in both normotensive rats and SHR, whereas i.c.v. infusion of an Ang 1–7 antagonist blunted baroreflex sensitivity of normotensive rats, but did not significantly alter the depressed baroreflex sensitivity of SHR (Oliveira *et al.*, 1996). This study suggests that stimulation of AT₁ receptors and Ang 1–7 actions have opposing effects on the baroreflex response, causing a decrease or increase in baroreflex gain respectively. The blunted baroreflex sensitivity in SHR may relate in part to diminished central actions of Ang 1–7. Within the NTS, AT₁ receptor blockade facilitates baroreflex control of heart rate and, conversely, AT₁ receptor activation by exogenous Ang II depresses both sympathetic and vagal components of baroreflex-induced bradycardia, indicating that Ang II decreases baroreflex gain (Casto & Phillips, 1985; Campagnole-Santos *et al.*, 1988; Kasparov *et al.*, 1998; Matsumura *et al.*, 1998; Boscan *et al.*, 2001). Ang II-induced suppression of the baroreflex response was attenuated by inhibition of conversion of Ang II to Ang III, suggesting that part of the action of Ang II may result from conversion to Ang III (Luoh & Chan, 1998). While Ang II mediates its effects via AT₁ receptors, it appears that Ang III acts on both AT₁ and AT₂ receptors to depress the baroreflex response (Luoh & Chan, 1998). SHR and TGR mRen2 rats exhibit high medullary Ang II content and increased Ang II binding densities within the NTS (Gutkind *et al.*, 1988; Senanayake *et al.*, 1994; Morishita *et al.*, 1995). Baroreflex control of heart rate in these hypertensive models is blunted compared to control rats and may be reversed by AT₁ receptor blockade within the NTS (Matsumura *et al.*, 1998; Diz *et al.*, 2002), indicating that increased AT₁ receptor stimulation within the NTS results in blunting of the baroreflex in these hypertensive models. Ang 1–7 actions in the NTS also appear to contribute to baroreflex modulation exerting a tonic facilitatory role on the bradycardic component (Chaves *et al.*, 2000). In SHR, sensitivity to Ang 1–7 within the NTS is decreased and may therefore contribute to the blunted baroreflex control in this model (Chaves *et al.*, 2000). In addition, Colombari *et al.* (2001) have suggested that enhanced chemoreceptor afferent input to the commissural NTS in SHR contributes to enhanced RVLM vasomotor neuron activity and may therefore contribute to hypertension in this model.

In summary, studies utilizing different approaches and animal models have verified that a hyperactive brain RAS mediates hypertension. Increased brain RAS activity may result in the development and maintenance of hypertension via both AT₁ receptor activation and endogenous Ang 1–7 actions on RVLM vasomotor neurons. In addition, AT₁ receptor-mediated suppression of afferent baroreceptor feedback as well as a reduced sensitivity to Ang 1–7 within the NTS may also contribute to the development of hypertension.

Cellular and molecular basis for brain RAS dysfunction in hypertension

In spite of identification and characterization of mechanisms that contribute to dysfunction of the brain RAS in hypertension, little is known about the cellular and molecular basis of this dysfunction. Central AT₁ receptor-mediated actions of Ang II are mediated by facilitation of excitatory transmission via catecholamines (Jenkins *et al.*, 1996; Raizada *et al.*, 1999), glutamate (Ferguson *et al.*, 2001) and substance P (Paton & Kasparov, 1999; Diz *et al.*, 2002), as well as enhanced inhibitory GABAergic neurotransmission (Paton *et al.*, 2001). A number of studies have provided evidence that the pressor effects of Ang II are mediated by noradrenergic neurotransmission. AT₁ receptors are localized on noradrenergic neurons in specific brain nuclei/areas (Yang *et al.*, 1997). Central Ang II administration enhances NA release in the PVN in parallel to the pressor response (Stadler *et al.*, 1992), and increases tyrosine hydroxylase (TH)mRNA and activity in the hypothalamus and brainstem (Yu *et al.*, 1996). In addition, central catecholaminergic depletion or noradrenergic antagonist administration prevents the pressor response to central Ang II, indicating that the Ang II-induced pressor response is mediated by NA (Camacho & Phillips, 1981; Jones, 1984; Bellin *et al.*, 1987). In hypertensive SHR, Ang II-induced increases in TH activity and mRNA within the hypothalamus and brainstem are enhanced compared to WKY rats (Yu *et al.*, 1996). Enhanced Ang II-induced NA neuromodulation and alterations in AT₁ signal transduction mechanisms that mediate the NA neuromodulation may therefore contribute to hypertension in the SHR.

AT₁ receptor signal transduction and alterations in hypertension

We have utilized primary neuronal cultures derived from the hypothalamus and brainstem of newborn prehypertensive SHR and normotensive WKY rats to elucidate Ang II-mediated signal transduction pathways and identify differences that could contribute to the overactive brain RAS in the SHR. Similar to Ang receptor subtype expression *in vivo*, SHR neuronal cultures exhibit increased AT₁ receptor gene expression and functional receptors compared to WKY cultures (Raizada *et al.*, 1984; 1993). A large percentage of the AT₁ receptors are localized on catecholaminergic neurons (Raizada *et al.*, 1999). Ang II, via AT₁ receptor-mediated signaling events, rapidly results in release of NA in these neuronal cultures, which we have termed an evoked response (Raizada *et al.*, 1999). Persistent AT₁ receptor stimulation results in increased activity and transcription of catecholamine synthesizing enzymes such as TH and dopamine β -hydroxylase (D- β H), and the NA transporter (NAT), that is, enhanced responses to Ang II (Raizada *et al.*, 1999). These observations are consistent with Ang II-induced NA synthesis and release observed following central injections *in vivo* (Sumners & Phillips, 1983; Stadler *et al.*, 1992; Yu *et al.*, 1996). In SHR neuronal cultures, Ang II-induced NA release and increases in NAT and TH transcription, and TH activity are enhanced (Lu *et al.*, 1996b; Raizada *et al.*, 1996), consistent with augmented *in vivo* Ang II stimulation of TH activity and mRNA in adult (hypertensive) SHR (Yu *et al.*, 1996). These neuronal cultures therefore provide a simple *in vitro* system in which we are able

to mimic augmented Ang II actions on NA modulation in adult SHR, and preclude nonspecific influences that would confound results obtained from studies in the intact brain.

Similar to AT₁ receptor signaling in peripheral tissue (Inagami & Eguchi, 2000; Touyz & Schiffrin, 2000; Sayeski & Bernstein, 2001), brain AT₁ receptors appear to signal via multiple pathways. In neuronal cultures, Ang II, *via* the AT₁

receptor, activates Gq, increases phospholipase C (PLC) activity and phosphoinositide (PI) hydrolysis, resulting in increased cytosolic free Ca²⁺ and subsequent activation of Ca²⁺-dependent enzymes such as protein kinase C (PKC) and calcium/calmodulin-dependent protein kinase II (CaMKII) (Raizada *et al.*, 1999). Seltzer *et al.* (1995) reported an AT₁ receptor-mediated increase in PI turnover in the median eminence providing support for this pathway *in vivo*. Neuronal AT₁ receptors also signal *via* a PLC-dependent Ras–Raf–mitogen-activated protein (MAP) kinase pathway (Raizada *et al.*, 1999). Activation of this pathway is essential for Ang II-induced increases in transcription of TH, D-βH and the NAT, and TH activity (Yang *et al.*, 1996; Yang & Raizada, 1998; Figure 1a). Similar to Ang II, Ang III also increases TH activity and NA release *via* an AT₁ receptor–PLC-dependent pathway in rat hypothalamic tissue (Rodriguez-Campos *et al.*, 2000).

Furthermore, Ang II induces transcription factors such as Fos and Jun by increasing *c-fos* and *c-jun* gene expression respectively (Yang *et al.*, 1996; Summers *et al.*, 2002), and increases activity of Fos-regulating kinase (FRK) and c-Jun NH₂-terminal kinase (JNK) (Huang *et al.*, 1998) which phosphorylate Fos and Jun prior to the formation of a fully active activating protein 1 (AP1) complex and translocation to the nucleus. In addition, AT₁ receptor activation results in increased binding activity at AP1 binding sites (Lu *et al.*, 1996a; Figure 1a). We have therefore proposed that Ang II-induced transcription of TH, D-βH and NAT results from the interaction of the active AP1 transcription complex with AP1 binding sites in the promoter regions of these genes (Raizada *et al.*, 1999). The production of Fos and Jun is mediated by MAP kinase activity, whereas the activity of FRK and JNK is dependent on PKC and phosphoinositide-3-kinase (PI3K) respectively (Yang *et al.*, 1996; Huang *et al.*, 1998; Summers

Figure 1 AT₁ receptor signal transduction pathways that result in transcriptional NA neuromodulation (a) and increased firing rate (b) in neuronal cultures. (a) AT₁ receptor activation increases the transcription of TH, D-βH and the NAT via a PLC-dependent Ras–Raf–MAP kinase pathway. This induces Fos and Jun by increasing *c-fos* and *c-jun* gene expression. PKC and PI3K mediate FRK and JNK activity, respectively, which in turn phosphorylate Fos and Jun, resulting in transactivation of the AP1 transcription complex. Interaction of the AP1 complex with AP1 binding sites in the promoter regions of TH, D-βH and the NAT results in transcription of these genes. A PI3K–PKB/Akt pathway (highlighted in red) uniquely mediates the augmented transcriptional NA neuromodulation in SHR neurons. Increased AP1 nuclear binding in SHR neurons may be due to enhanced PI3K-mediated JNK activity, resulting in subsequent increases in Jun phosphorylation and AP1 binding. (b) AT₁ receptor activation inhibits I_{Kv} and I_A, and stimulates I_{Ca} resulting in increased neuronal firing rate via PLC-mediated activation of PKC. PLC also activates CaMKII, which contributes to I_{Kv} inhibition. An additional signaling pathway that utilizes PI3K (pathway highlighted in red) mediates the enhanced Ang II-induced neuronal firing response in SHR neurons. Ang, angiotensin; AP1, activating protein 1; AT₁R, angiotensin type 1 receptor; [Ca²⁺]_i, intracellular calcium; CaMKII, calcium/calmodulin-dependent protein kinase II; DAG, diacylglycerol; D-βH, dopamine β-hydroxylase; FRK, Fos-regulating kinase; I_A, transient A type K⁺ current; I_{Ca}, total Ca²⁺ current; I_{Kv}, delayed rectifier K⁺ current; IP₃, inositol 1,4,5-triphosphate; JNK, c-Jun NH₂-terminal kinase; MAPK, mitogen-activated protein kinase; NA, noradrenaline; NAT, NA transporter; PI3K, phosphoinositide-3-kinase; PKB, protein kinase B; PKC, protein kinase C; PLC, phospholipase C; TH, tyrosine hydroxylase.

et al., 2002). It therefore appears that diverse signaling pathways are involved in the regulation of Ang II-induced NA neuromodulation, and altered regulation of one or more of these pathways may result in the augmented NA neuromodulation observed in the SHR.

Despite augmented Ang II-mediated NA neuromodulation in SHR neuronal cultures, AT₁ receptor-mediated regulation of the MAP kinase signaling pathway (Yang & Raizada, 1998) and induction of Fos and Jun are comparable in SHR and WKY neuronal cultures (Lu *et al.*, 1996a). Similarly, i.c.v. injections of Ang II caused a comparable stimulation of MAP kinase phosphorylation in the hypothalamus and brainstem of adult WKY and SHR (Yang & Raizada, 1998). In addition, bilateral microinjection of a MAP kinase inhibitor into the RVLM caused a similar percentage decrease in BP in SHR and WKY rats (Seyedabadi *et al.*, 2001). These studies indicate that the MAP kinase pathway contributes to NA neuromodulation and BP regulation to a similar extent in both strains. However, Ang II-mediated AT₁ receptor phosphorylation is greater in SHR compared to WKY neurons and was demonstrated to be MAP kinase dependent (Yang *et al.*, 1997). The reason for this discrepancy is not clear. Despite similar Ang II induction of Fos and Jun in WKY and SHR neuronal cultures, i.c.v. Ang II injections cause a greater increase in expression of Fos, Jun and Krox-24 in areas involved in cardiovascular homeostasis and osmoregulation such as the SFO, OVLT, PVN and the NTS, in hypertensive SHR compared to WKY rats (Blume *et al.*, 1997). Whether enhanced Ang II-induced expression of transcription factors in the adult SHR relates to the enhanced transcriptional NA neuromodulation in response to Ang II in this model of hypertension is yet to be determined.

In SHR neurons, in addition to the Ras–Raf MAP kinase pathway, a MAP kinase-independent signaling pathway that involves PI3K appears to modulate enhanced Ang II-mediated NA neuromodulation (Figure 1a, highlighted in red). Although AT₁ receptor activation results in comparable (~3.6-fold) stimulation of PI3K activity in WKY and SHR neuronal cultures, its effect in SHR neurons is more persistent (Yang & Raizada, 1999). In WKY cultures PI3K activity returns to control values within 30 min following Ang II stimulation whereas in SHR cultures a two-fold stimulation in activity was detected even an hour after Ang II treatment. In addition, the rate of nuclear translocation of PI3K is greater in SHR *versus* WKY neuronal cultures.

Consistent with Ang II stimulation of PI3K activity in neuronal cultures, central Ang II injections in adult SHR caused more persistent increases in hypothalamic PI3K activity compared to WKY rats (Yang & Raizada, 1999). PI3K inhibition resulted in an ~50% attenuation of Ang II-induced stimulation of TH and NAT mRNA and (³H)NA uptake in SHR neuronal cultures whereas it had no effect in WKY neurons (Yang & Raizada, 1999). Furthermore, combined inhibition of MAP kinase and PI3K activity abolished Ang II-induced increases in TH and NAT mRNA in the SHR cultures. Ang II causes a five-fold greater induction of nuclear AP1 binding activity in SHR *versus* WKY neurons. PI3K inhibition decreased AP1 binding activity in nuclear fractions of SHR neurons to levels similar to that in WKY neurons, whereas it had no effect on AP1 binding activity in WKY neurons (Yang & Raizada, 1999). Enhanced AP1 binding activity in SHR neuronal nuclear fractions may possibly be due to enhanced PI3K-mediated

JNK activity, which would increase phosphorylation of Jun and may therefore result in increased AP1 binding. Consistent with enhanced PI3K signaling in SHR neurons, Ang II also causes an enhanced and more persistent stimulation of protein kinase B (PKB/Akt) activity (Yang & Raizada, 1999; Figure 1a, highlighted in red), an established downstream kinase in the PI3K signaling pathway. AT₁ receptor inhibition and PI3K inhibition abolished PKB/Akt stimulation, suggesting that the AT₁ receptor–PI3K pathway mediates PKB/Akt stimulation (Yang & Raizada, 1999). These studies indicate that AT₁ receptor activation in SHR neurons causes enhanced PI3K-mediated AP1 binding activity and PKB/Akt activity, resulting in the augmented NA neuromodulation in SHR neurons. This PI3K pathway does not appear to mediate NA neuromodulation in WKY neurons, but has been implicated in Ang II-induced neuritogenesis (Yang *et al.*, 2001).

Ang II-evoked NA release results from modulation of neuronal electrical activity via effects on membrane ion channels and their dependent currents. Ang II inhibits delayed rectifier K⁺ current (*I*_{Kv}) and transient A type K⁺ current (*I*_A), stimulates total Ca²⁺ current, and results in increases in neuronal firing rate in neuronal cultures (Sumners *et al.*, 2002; Figure 1b). These effects are mediated by the AT₁ receptor as they occur in the presence of an AT₂ receptor antagonist and are abolished by losartan, an AT₁ receptor antagonist. These effects are consistent with the effects of Ang II on *I*_A and neuronal firing in SFO, PVN and SON neurons as well as on neuronal firing rate in MnPO and RVLM neurons in brain slices or *in situ* (Felix & Schlegel, 1978; Suga & Suzuki, 1979; Tasker & Dudek, 1991; Yang *et al.*, 1992; Armstrong, 1995; Ferguson & Li, 1996; Li & Ferguson, 1996; Bai & Renaud, 1998). PKC inhibition attenuates Ang II-induced decreases in *I*_A and *I*_{Kv} and abolishes Ang II-evoked increases in total Ca²⁺ current, indicating that Ang II effects on these ion channel currents are either partly or wholly mediated by PKC (Sumners *et al.*, 1996; Wang *et al.*, 1997; Zhu *et al.*, 1999). Studies utilizing anti-PKC α antibodies and PKC α antisense oligonucleotides implicate this isozyme in mediating Ang II-induced changes in *I*_{Kv} (Sumners *et al.*, 2002).

Concurrent inhibition of PKC and CaMKII completely abolished Ang II effect on *I*_{Kv}, indicating that PKC and CaMKII mediate this effect (Zhu *et al.*, 1999). Both PKC and CaMKII also mediate Ang II-induced increases in neuronal firing rate (Sun *et al.*, 2002a, b).

In SHR cultures, AT₁ receptor activation results in an augmented increase in neuronal firing rate (~65%) compared to WKY neurons under the same conditions (Sun *et al.*, 2002a, b). This is consistent with enhanced Ang II-induced depolarization and firing of RVLM neurons in neonatal SHR compared to WKY rats (Matsuura *et al.*, 2002). PKC and CaMKII inhibitors completely blocked Ang II-induced firing in WKY neuronal cultures whereas it only attenuated it by ~50% in SHR cultures, suggesting that an additional signaling pathway mediates the enhanced Ang II neuronal firing response in SHR neurons. Inhibition of PI3K attenuated Ang II-mediated neuronal firing in SHR but not in WKY neurons, indicating that a signaling pathway utilizing PI3K may mediate the augmented Ang II-induced response in SHR neurons (Sun *et al.*, 2002a, b; Figure 1b, highlighted in red).

From the preceding discussion, it is apparent that both AT₁ receptor-mediated NA neuromodulation and increases in neuronal firing rate are partly mediated by PI3K in SHR but

not WKY neurons. It therefore appears that a signaling pathway involving PI3K may mediate the augmented Ang II-induced NA neuromodulation and neuronal firing in the SHR. PI3K-dependent NA neuromodulation and neuronal firing occurs in neurons from prehypertensive rats and is therefore due to an intrinsic difference in the SHR rather than a compensatory change in response to an increase in BP. The relevance of this pathway in BP regulation, and hence hypertension in this model, was demonstrated by Seyedabadi *et al.* (2001). Bilateral microinjections of a PI3K inhibitor into the RVLM of adult SHR resulted in an ~35% decrease in BP, resulting in pressures similar to that in untreated or vehicle-treated WKY rats, but had no effect on BP in WKY rats. The decrease in BP in SHR was gradual (requiring hours), suggesting that PI3K mediates the elevated BP in SHR possibly via transcriptional or translational effects.

The PI3K inhibitor also blunted enhanced Ang II-induced pressor responses in SHR to levels comparable to responses in WKY rats. These studies therefore implicate a PI3K-dependent pathway in mediating the hypertension in SHR possibly via Ang II-evoked increases in neuronal firing and enhanced NA transcriptional neuromodulation.

Perspectives and future directions

In recent years, clear progress has been made in our understanding of the role of the brain RAS in the pathogenesis of hypertension. Genetic models of hypertension, such as the SHR, exhibit a hyperactive endocrine and tissue RAS, making it difficult to distinguish between the relative contributions of the two systems in functional studies. Earlier transgenic models have also been plagued by the same limitation. Recent advances in antisense strategies, *in vivo* gene transfer and transgenic techniques have enabled the development of models that exhibit brain- or nuclei/area-specific gain or loss of function. Studies utilizing these techniques have helped to clarify the role of specific components of the brain RAS in mediating hypertension. Progress has also been made in understanding the altered cellular and molecular basis for brain RAS dysfunction in hypertension. Studies

have demonstrated that augmented Ang II-induced NA neuromodulation and hypertension is uniquely mediated by a PI3K-dependent signaling pathway. One of our challenges is to utilize our understanding of the brain RAS dysfunction in hypertension for the development of improved therapeutic intervention in hypertension. For example, the PI3K-mediated NA neuromodulation may present a potential target for brain/cell type-specific targeted genetic regulation using gene transfer techniques. Another challenge is to identify other genes whose expression is also uniquely linked to the development of hypertension. The development of high-throughput microarray gene profiling technology has enabled the assessment of the expression of a large number of genes within a single experiment. This technology provides tremendous potential for the elucidation of genetic regulation of signaling pathways and identification of target genes that are activated or repressed by the brain RAS. We are currently using this approach to identify genes that encode intracellular signaling proteins and target genes that are regulated by the brain RAS and contribute to the altered responsiveness to Ang II in hypertensive models (Francis *et al.*, 2001; Veerasingham *et al.*, 2002). The combination of microarray gene profiling with validation of the altered expression of identified genes, cellular and *in vivo* physiological approaches will further our understanding of brain RAS dysfunction in hypertension. Using this approach we have identified a decrease in central γ -adducin expression in models of hypertension that express a hyperactive brain RAS (Yang *et al.*, 2002). Further studies will be required to determine whether this decrease in γ -adducin contributes to the development of hypertension in these models. The identification of genes that are uniquely linked to the development or maintenance of hypertension would provide novel targets of potential therapeutic value for the control, and possibly the cure of hypertension.

This work was supported by the National Heart, Lung, and Blood Institute Grant 33610. S.J.V. was supported by a fellowship from the Canadian Institutes of Health Research.

References

- ALLEN, A.M. (2001). Blockade of angiotensin AT₁ receptors in the rostral ventrolateral medulla of spontaneously hypertensive rats reduces blood pressure and sympathetic nerve discharge. *J. Renin – Angiotensin – Aldosterone Syst.*, **2**, S120 – S124.
- ALLEN, A.M. (2002). Inhibition of the hypothalamic paraventricular nucleus in spontaneously hypertensive rats dramatically reduces sympathetic vasomotor tone. *Hypertension*, **39**, 275 – 280.
- ALLEN, A.M., MACGREGOR, D.P., MCKINLEY, M.J. & MENDEL-SOHN, F.A. (1999). Angiotensin II receptors in the human brain. *Regul. Pept.*, **79**, 1 – 7.
- ANDERSON, E.A., SINKEY, C.A., LAWTON, W.J. & MARK, A.L. (1989). Elevated sympathetic nerve activity in borderline hypertensive humans. Evidence from direct intraneural recordings. *Hypertension*, **14**, 177 – 183.
- ANDRESEN, M.C. & YANG, M. (1989). Arterial baroreceptor resetting: contributions of chronic and acute processes. *Clin. Exp. Pharmacol. Physiol.*, **15**(Suppl), 19 – 30.
- ARMSTRONG, W.E. (1995). Morphological and electrophysiological classification of hypothalamic supraoptic neurons. *Prog. Neurobiol.*, **47**, 291 – 339.
- ARRIBAS, S.M., ALONSO, M.J., MARIN, J., FERNANDES, F., LLERGO, J.L., SANCHEZ-FERRER, C.F. & SALAICES, M. (1996). Noradrenergic transmission in the tail artery of hypertensive rats transgenic for the mouse renin gene Ren-2. *J. Auton. Pharmacol.*, **16**, 69 – 77.
- AVERILL, D.B. & DIZ, D.I. (2000). Angiotensin peptides and baroreflex control of sympathetic outflow: pathways and mechanisms of the medulla oblongata. *Brain Res. Bull.*, **51**, 119 – 128.
- AVERILL, D.B., TSUCHIHASHI, T., KHOSLA, M.C. & FERRARIO, C.M. (1994). Losartan, non-peptide angiotensin II-type I (AT₁) receptor antagonist, attenuates pressor and sympathoexcitatory responses evoked by angiotensin II and L-glutamate in rostral ventrolateral medulla. *Brain Res.*, **665**, 175 – 180.
- BAI, D. & RENAUD, L.P. (1998). ANG II AT₁ receptors induce depolarization and inward current in rat median preoptic neurons *in vitro*. *Am. J. Physiol.*, **275**, R632 – R639.
- BELLIN, S.I., BHATNAGAR, R.K. & JOHNSON, A.K. (1987). Periventricular noradrenergic systems are critical for angiotensin-induced drinking and blood pressure responses. *Brain Res.*, **403**, 105 – 112.

- BERECEK, K.H., KIRK, K.A., NAGAHAMA, S. & OPARIL, S. (1987). Sympathetic function in spontaneously hypertensive rats after chronic administration of captopril. *Am. J. Physiol.*, **252**, H796–H806.
- BLUME, A., LEBRUN, C.J., HERDEGEN, T., BRAVO, R., LINZ, W., MOLLENHOFF, E. & UNGER, T. (1997). Increased brain transcription factor expression by angiotensin in genetic hypertension. *Hypertension*, **29**, 592–598.
- BORGONIO, A., PUMMER, S., WITTE, K. & LEMMER, B. (2001). Reduced baroreflex sensitivity and blunted endogenous nitric oxide synthesis precede the development of hypertension in TGR(mREN2)27 rats. *Chronobiol. Int.*, **18**, 215–226.
- BOSCAN, P., ALLEN, A.M. & PATON, J.F. (2001). Baroreflex inhibition of cardiac sympathetic outflow is attenuated by angiotensin II in the nucleus of the solitary tract. *Neuroscience*, **103**, 153–160.
- CABASSI, A., VINCI, S., CANTONI, A.M., QUARTIERI, F., MOSCHINI, L., CAVAZZINI, S., CAVATORTA, A. & BORGHETTI, A. (2002). Sympathetic activation in adipose tissue and skeletal muscle of hypertensive rats. *Hypertension*, **39**, 656–661.
- CAMACHO, A. & PHILLIPS, M.I. (1981). Separation of drinking and pressor responses to central angiotensin by monoamines. *Am. J. Physiol.*, **240**, R106–R113.
- CAMPAGNOLE-SANTOS, M.J., DIZ, D.I. & FERRARIO, C.M. (1988). Baroreceptor reflex modulation by angiotensin II at the nucleus tractus solitarius. *Hypertension*, **11**, I167–I171.
- CASTO, R. & PHILLIPS, M.I. (1985). Neuropeptide action in nucleus tractus solitarius: angiotensin specificity and hypertensive rats. *Am. J. Physiol.*, **249**, R341–R347.
- CHAVES, G.Z., CALIGIORNE, S.M., SANTOS, R.A., KHOSLA, M.C. & CAMPAGNOLE-SANTOS, M.J. (2000). Modulation of the baroreflex control of heart rate by angiotensin (1–7) at the nucleus tractus solitarius of normotensive and spontaneously hypertensive rats. *J. Hypertens.*, **18**, 1841–1848.
- CIRIELLO, J., KLINE, R.L., ZHANG, T.X. & CAVERSON, M.M. (1984). Lesions of the paraventricular nucleus alter the development of spontaneous hypertension in the rat. *Brain Res.*, **310**, 355–359.
- CLAUSMEYER, S., REINECKE, A., FARRENKOPF, R., UNGER, T. & PETERS, J. (2000). Tissue-specific expression of a rat renin transcript lacking the coding sequence for the prefragment and its stimulation by myocardial infarction. *Endocrinology*, **141**, 2963–2970.
- COLOMBARI, E., SATO, M.A., CRAVO, S.L., BERGAMACHI, C.T., CAMPOS JR., R.R. & LOPES, O.U. (2001). Role of the medulla oblongata in hypertension. *Hypertension*, **38**, 549–554.
- COUTO, A.S., BALTATU, O., SANTOS, R.A., GANTEN, D., BADER, M. & CAMPAGNOLE-SANTOS, M.J. (2002). Differential effects of angiotensin II and angiotensin-(1–7) at the nucleus tractus solitarius of transgenic rats with low brain angiotensinogen. *J. Hypertens.*, **20**, 919–925.
- CULMAN, J., HOHLE, S., QADRI, F., EDLING, O., BLUME, A., LEBRUN, C. & UNGER, T. (1995). Angiotensin as neuromodulator/neurotransmitter in central control of body fluid and electrolyte homeostasis. *Clin. Exp. Hypertens.*, **17**, 281–293.
- CURNOW, K.M., PASCOE, L. & WHITE, P.C. (1992). Genetic analysis of the human type-1 angiotensin II receptor. *Mol. Endocrinol.*, **6**, 1113–1118.
- DAMPNEY, R.A.L., FONTES, M.A.P., HIROOKA, Y., HORIUCHI, J., POTTS, P.D. & TAGAWA, T. (2002). Role of angiotensin II receptors in the regulation of vasomotor neurons in the ventrolateral medulla. *Clin. Exp. Pharm. Physiol.*, **29**, 467–472.
- DAVISSON, R.L., OLIVERIO, M.I., COFFMAN, T.M. & SIGMUND, C.D. (2000). Divergent functions of angiotensin II receptor isoforms in the brain. *J. Clin. Invest.*, **106**, 103–106.
- DE WARDENER, H. (2001). The hypothalamus and hypertension. *Physiol. Rev.*, **81**, 1559–1658.
- DIZ, D.I., JESSUP, J.A., WESTWOOD, B.M., BOSCH, S.M., VINSANT, S., GALLAGHER, P.E. & AVERILL, D.B. (2002). Angiotensin peptides as neurotransmitters/neuromodulators in the dorsomedial medulla. *Clin. Exp. Pharm. Physiol.*, **29**, 473–482.
- ELTON, T.S., STEPHAN, C.C., TAYLOR, G.R., KIMBALL, M.G., MARTIN, M.M., DURAND, J.N. & OPARIL, S. (1992). Isolation of two distinct type I angiotensin II receptor genes. *Biochem. Biophys. Res. Commun.*, **184**, 1067–1073.
- ESLER, M.J.G., KORNER, P., WILLETT, I., DUDLEY, F., HASKING, G., ANDERSON, W. & LABERT, G. (1988). The assessment of human sympathetic nervous system activity from measurements of norepinephrine turnover. *Hypertension*, **11**, 3–20.
- FABER, J.E. & BRODY, M.J. (1984). Central nervous system action of angiotensin during onset of renal hypertension in awake rats. *Am. J. Physiol.*, **247**, H349–H360.
- FELIX, D. & SCHLEGEL, W. (1978). Angiotensin receptive neurones in the subfornical organ. Structure – activity relations. *Brain Res.*, **149**, 107–116.
- FERGUSON, A.V. & LI, Z. (1996). Whole cell patch recordings from forebrain slices demonstrate angiotensin II inhibits potassium currents in subfornical organ neurons. *Regul. Pept.*, **66**, 55–58.
- FERGUSON, A.V., WASHBURN, D.L. & LATCHFORD, K.J. (2001). Hormonal and neurotransmitter roles for angiotensin in the regulation of central autonomic function. *Exp. Biol. Med.*, **226**, 85–96.
- FLORAS, J. (1992). Epinephrine and the genesis of hypertension. *Hypertension*, **19**, 1–18.
- FONTES, M.A., PINGE, M.C., NAVES, V., CAMPAGNOLE-SANTOS, M.J., LOPES, O.U., KHOSLA, M.C. & SANTOS, R.A. (1997). Cardiovascular effects produced by microinjection of angiotensins and angiotensin antagonists into the ventrolateral medulla of freely moving rats. *Brain Res.*, **750**, 305–310.
- FONTES, M.A., SILVA, L.C., CAMPAGNOLE-SANTOS, M.J., KHOSLA, M.C., GUERTZENSTEIN, P.G. & SANTOS, R.A. (1994). Evidence that angiotensin-(1–7) plays a role in the central control of blood pressure at the ventro-lateral medulla acting through specific receptors. *Brain Res.*, **665**, 175–180.
- FONTES, M.A.P., BALTATU, O., CALIGIORNE, S.M., CAMPAGNOLE-SANTOS, M.J., GANTEN, D., BADER, M. & SANTOS, R.A.S. (2000). Angiotensin peptides acting at rostral ventrolateral medulla contribute to hypertension of TGR(mREN2)27 rats. *Physiol. Genom.*, **2**, 137–142.
- FRANCIS, S.C., YANG, H., VEERASINGHAM, S., SUMNERS, C. & RAIZADA, M.K. (2001). Differential gene expression profiling in SHR versus WKY brains. *Hypertension*, **38**, 496 (Abstract).
- GANTEN, D., HERMANN, K., BAYER, C., UNGER, T. & LANG, R.E. (1983). Angiotensin synthesis in the brain and increased turnover in hypertensive rats. *Science*, **221**, 869–871.
- GOLDSTEIN, D. (1981). Plasma norepinephrine in essential hypertension: a study of the studies. *Hypertension*, **27**, 520–529.
- GRASSI, G., CATTANEO, B.M., SERAVALLE, G., LANFRANCHI, A. & MANCIA, G. (1998). Baroreflex control of sympathetic nerve activity in essential and secondary hypertension. *Hypertension*, **31**, 68–72.
- GUTKIND, J.S., KURIHARA, M., CASTREN, E. & SAAVEDRA, J.M. (1988). Increased concentration of angiotensin II binding sites in selected brain areas of spontaneously hypertensive rats. *J. Hypertens.*, **6**, 79–84.
- GUZZETTI, S., PICCALUGA, E., CASATI, R., CERUTTI, S., LOMBARDI, F., PAGANI, M. & MALLIANI, A. (1988). Sympathetic predominance in essential hypertension: a study employing spectral analysis of heart rate variability. *J. Hypertens.*, **6**, 711–717.
- HAYASHI, J., TAKEDA, K., KAWASAKI, S., NAKAMURA, Y., OGURO, M., NAKATA, T., TANABE, S., LEE, L.C., SASAKI, S. & NAKAGAWA, M. (1988). Central attenuation of baroreflex by angiotensin II in normotensive and spontaneously hypertensive rats. *Am. J. Hypertens.*, **1**, 15S–22S.
- HERMANN, K., MCDONALD, W., UNGER, T., LANG, R.E. & GANTEN, D. (1984). Angiotensin biosynthesis and concentrations in brain of normotensive and hypertensive rats. *J. Physiol. (Paris)*, **79**, 471–480.
- HIROOKA, Y., POTTS, P.D. & DAMPNEY, R.A.L. (1997). Role of angiotensin II receptor subtypes in mediating the sympathoexcitatory effects of exogenous and endogenous angiotensin peptides in the rostral ventrolateral medulla of the rabbit. *Brain Res.*, **772**, 107–114.
- HOGARTY, D.C., SPEAKMAN, E.A., PUIG, V. & PHILLIPS, M.I. (1992). The role of angiotensin, AT₁ and AT₂ receptors in the pressor, drinking and vasopressin responses to central angiotensin. *Brain Res.*, **586**, 289–294.
- HU, L., ZHU, D.N., YU, Z., WANG, J.Q., SUN, Z.J. & YAO, T. (2002). Expression of angiotensin II type 1 AT(1) receptor in the rostral ventrolateral medulla in rats. *J. Appl. Physiol.*, **92**, 2153–2161.

- HUANG, B.S. & LEENEN, F.H. (1998). Both brain angiotensin II and 'ouabain' contribute to sympathoexcitation and hypertension in Dahl S rats on high salt intake. *Hypertension*, **32**, 1028–1033.
- HUANG, X.C., DENG, T. & SUMNERS, C. (1998). Angiotensin II stimulates activation of Fos-regulating kinase and c-Jun NH2-terminal kinase in neuronal cultures from rat brain. *Endocrinology*, **139**, 245–251.
- HUTCHINSON, J.S., MENDELSON, F.A. & DOYLE, A.E. (1980). Blood pressure responses of conscious normotensive and spontaneously hypertensive rats to intracerebroventricular and peripheral administration of captopril. *Hypertension*, **2**, 546–550.
- INAGAMI, T. & EGUCHI, S. (2000). Angiotensin II-mediated vascular smooth muscle cell growth signaling. *Braz. J. Med. Biol. Res.*, **33**, 619–624.
- ITAYA, Y., SUZUKI, H., MATSUKAWA, S., KONDO, K. & SARUTA, T. (1986). Central renin-angiotensin system and the pathogenesis of DOCA-salt hypertension in rats. *Am. J. Physiol.*, **251**, H261–H268.
- ITO, S., KOMATSU, K., TSUKAMOTO, K., KANMATSUSE, K. & SVED, A.F. (2002). Ventrolateral medulla AT₁ receptors support blood pressure in hypertensive rats. *Hypertension*, **40**, 552–559.
- ITO, S., KOMATSU, K., TSUKAMOTO, K. & SVED, A.F. (2000). Excitatory amino acids in the rostral ventrolateral medulla support blood pressure in spontaneous hypertensive rats. *Hypertension*, **35**, 413–417.
- ITO, S. & SVED, A.F. (1996). Blockade of angiotensin receptors in rat rostral ventrolateral medulla removes excitatory vasomotor tone. *Am. J. Physiol.*, **270**, R1317–R1323.
- ITO, S. & SVED, A.F. (2000). Pharmacological profile of depressor response elicited by sarthran in rat ventrolateral medulla. *Am. J. Physiol.*, **279**, H2961–H2966.
- JENKINS, T.A., ALLEN, A.M., CHAI, S.Y., MACGREGOR, D.P., PAXINOS, G. & MENDELSON, F.A. (1996). Interactions of angiotensin II with central dopamine. *Adv. Exp. Med. Biol.*, **396**, 93–103.
- JONES, D.L. (1984). Injections of phentolamine into the anterior hypothalamus-preoptic area of rats blocks both pressor and drinking responses produced by central administration of angiotensin II. *Brain Res. Bull.*, **13**, 127–133.
- KAGIYAMA, S., TSUCHIHASHI, T., ABE, L., MATSUMURA, K. & FUJISHIMA, G. (1999). Antisense inhibition of angiotensinogen attenuates vasopressin release in the paraventricular hypothalamic nucleus of spontaneously hypertensive rats. *Brain Res.*, **829**, 120–124.
- KAGIYAMA, S., VARELA, A., PHILLIPS, M.I. & GALLI, S.M. (2001). Antisense inhibition of brain rennin-angiotensin system decreased blood pressure in chronic 2-kidney, 1 clip hypertensive rats. *Hypertension*, **37**, 371–375.
- KASPAROV, S., BUTCHER, J.W. & PATON, J.F.R. (1998). Angiotensin II receptors within the nucleus of the solitary tract mediate the developmental attenuation of the baroreceptor vagal reflex in pre-weaned rats. *J. Auton. Nerv. Syst.*, **74**, 160–168.
- KOMATUS, C., SHIBATA, K. & FURUKAWA, T. (1996). The developmental increase of the AT₁A, but not the AT₁B, receptor mRNA level at the preoptic area in spontaneously hypertensive rats. *Life Sci.*, **58**, 1109–1121.
- LANTELME, P., CERUTTI, C., LO, M., PAULTRE, C.Z. & DUCHER, M. (1998). Mechanisms of spontaneous baroreflex impairment in Lyon hypertensive rats. *Am. J. Physiol.*, **275**, R920–R925.
- LAZARTIGUES, E., DUNLAY, S.M., LOIHL, A.K., SINNAYAH, P., LANG, J.A., ESPELUND, J.J., SIGMUND, C.D. & DAVISSON, R.L. (2002). Brain-selective overexpression of angiotensin (AT₁) receptors causes enhanced cardiovascular sensitivity in transgenic mice. *Circ. Res.*, **90**, 617–624.
- LEE-KIRSCH, M.A., GAUDET, F., CARDOSO, M.C. & LINDPAINTNER, K. (1999). Distinct renin isoforms generated by tissue-specific transcription initiation and alternative splicing. *Circ. Res.*, **84**, 240–246.
- LEENEN, F.H., RUZICKA, M. & HUANG, B.S. (2002). The brain and salt-sensitive hypertension. *Curr. Hypertens. Rep.*, **4**, 129–135.
- LENKEI, Z., CORVOL, P. & LLORENS-CORTES, C. (1995). The angiotensin receptor subtype AT₁A predominates in rat forebrain areas involved in blood pressure, body fluid homeostasis and neuroendocrine control. *Brain Res. Mol. Brain Res.*, **30**, 53–60.
- LENKEI, Z., PALKOVITS, M., CORVOL, P. & LLORENS-CORTES, C. (1997). Expression of angiotensin II type-1 (AT₁) and type-2 (AT₂) receptor mRNAs in the adult rat brain: a functional neuroanatomical review. *Front. Neuroendocrinol.*, **18**, 383–439.
- LEWIS, J.L., SERIKAWA, T. & WARNOCK, D.G. (1993). Chromosomal localization of angiotensin II type 1 receptor isoforms in the rat. *Biochem. Biophys. Res. Commun.*, **194**, 677–682.
- LI, Z. & FERGUSON, A.V. (1996). Electrophysiological properties of paraventricular magnocellular neurons in rat brain slices. Modulation of I_A by angiotensin II. *Neuroscience*, **71**, 133–145.
- LI, Z., IWAI, M., WU, L., SHIUCHI, T., JINNO, T., CUI, T.-X. & HORIUCHI, M. (2003). Role of AT₂ receptor in the brain in regulation of blood pressure and water intake. *Am. J. Physiol.*, **284**, H116–H121.
- LIN, K.S., CHAN, J.Y. & CHAN, S.H.H. (1997). Involvement of AT₂ receptors at NRVL in tonic baroreflex suppression by endogenous angiotensins. *Am. J. Physiol.*, **272**, H2204–H2210.
- LIN, K.S., CHAN, S.H.H. & CHAN, J.Y.H. (2001). Tonic suppression of spontaneous baroreceptor reflex by endogenous angiotensins via AT₂ subtype receptors at nucleus reticularis ventrolateralis in the rat. *Synapse*, **40**, 85–94.
- LLORENS-CORTES, C. & MENDELSON, F.A.O. (2002). Organisation and functional role of the brain angiotensin system. *J. Renin-Angiotensin-Aldosterone Syst.*, **3**, S39–S48.
- LU, D., YANG, H. & RAIZADA, M.K. (1996a). Angiotensin II regulation of neuromodulation: downstream signaling mechanism from activation of mitogen-activated protein kinase. *J. Cell. Biol.*, **135**, 1609–1617.
- LU, D., YU, K., PADDY, M.R., ROWLAND, N.E. & RAIZADA, M.K. (1996b). Regulation of norepinephrine transport system by angiotensin II in neuronal cultures of normotensive and spontaneously hypertensive rat brains. *Endocrinology*, **137**, 763–772.
- LUOH, H.F. & CHAN, S.H. (1998). Participation of AT₁ and AT₂ receptor subtypes in the tonic inhibitory modulation of baroreceptor reflex response by endogenous angiotensins at the nucleus tractus solitarius in the rat. *Brain Res.*, **782**, 73–82.
- MATSUDA, T., SHIBATA, K., ABE, M., TOMONAGA, M. & FURUKAWA, T. (1987). Potentiation of pressor response to angiotensin II at the preoptic area in spontaneously hypertensive rat. *Life Sci.*, **41**, 749–754.
- MATSUKAWA, T., GOTOH, E., HASEGAWA, O., MIYAJIMA, E., SHIONOIRI, H., TOCHIKUBO, O. & ISHII, M. (1991a). Reduced arterial baroreflex control of muscle sympathetic nerve activity in young borderline hypertensives. *Funct. Neurol.*, **6**, 113–120.
- MATSUKAWA, T., GOTOH, E., HASEGAWA, O., SHIONOIRI, H., TOCHIKUBO, O. & ISHII, M. (1991b). Reduced baroreflex changes in muscle sympathetic nerve activity during blood pressure elevation in essential hypertension. *J. Hypertens.*, **9**, 537–542.
- MATSUMURA, K., AVERILL, D.B. & FERRARIO, C.M. (1998). Angiotensin II acts at AT₁ receptors in the nucleus of the solitary tract to attenuate the baroreceptor reflex. *Am. J. Physiol.*, **275**, R1611–R1619.
- MATSUURA, T., KUMAGAI, H., KAWAI, A., ONIMARU, H., IMAI, M., OSHIMA, N., SAKATA, K. & SARUTA, T. (2002). Rostral ventrolateral medulla neurons of neonatal Wistar-Kyoto and spontaneously hypertensive rats. *Hypertension*, **40**, 560–565.
- MCKINLEY, M.J., ALLEN, A.M., MATHAI, M.L., MAY, C., MCALLEN, R.M., OLDFIELD, B.J. & WEISINGER, R.S. (2001). Brain angiotensin and body fluid homeostasis. *Jpn. J. Physiol.*, **51**, 281–289.
- MIYAJIMA, E. & BUNAG, R.D. (1986). Impaired sympathetic baroreflexes in prehypertensive Dahl hypertension-sensitive rats. *Clin. Exp. Hypertens. A*, **8**, 1049–1061.
- MORIMOTO, S., CASSELL, M.D. & SIGMUND, C.D. (2002). Glial- and neuronal-specific expression of the renin-angiotensin system in brain alters blood pressure, water intake, and salt preference. *J. Biol. Chem.*, **277**, 33235–33241.
- MORISHITA, R., HIGAKI, J., NAKAMURA, Y., AOKI, M., YAMADA, K., MORIGUCHI, A., RAKUGI, H., TOMITA, N., TOMITA, S., YU, H., *et al.* (1995). Effect of an antihypertensive drug on brain angiotensin II levels in renal and spontaneously hypertensive rats. *Clin. Exp. Pharmacol. Physiol.*, **22**, 665–669.
- MURATANI, H., AVERILL, D.B. & FERRARIO, C.M. (1991). Effect of angiotensin II in ventrolateral medulla of spontaneously hypertensive rats. *Am. J. Physiol.*, **260**, R977–R984.

- MURPHY, T.J., ALEXANDER, R.W., GRIENDLING, K.K., RUNGE, M.S. & BERNSTEIN, K.E. (1991). Isolation of a cDNA encoding the vascular type-1 angiotensin II receptor. *Nature*, **351**, 233–236.
- NAKAMURA, S., MORIGUCHI, A., MORISHITA, R., YAMADA, K., NISHII, T., TOMITA, N., OHISHI, M., KANEDA, Y., HIGAKI, J. & OGIHARA, T. (1999). Activation of the brain angiotensin system by *in vivo* human angiotensin-converting enzyme gene transfer in rats. *Hypertension*, **34**, 302–308.
- NAKAMURA, Y., TAKEDA, K., NAKATA, T., HAYASHI, J., KAWASAKI, S., LEE, L.C., SASAKI, S., NAKAGAWA, M. & IJICHI, H. (1988). Central attenuation of aortic baroreceptor reflex in prehypertensive DOCA-salt-loaded rats. *Hypertension*, **12**, 259–266.
- NGUYEN, G., DELARUE, F., BURCKLE, C., BOUZHIR, L., GILLER, T. & SRAER, J.-D. (2002). Pivotal role of the renin/prorenin receptor in angiotensin II production and cellular responses to renin. *J. Clin. Invest.*, **109**, 1417–1427.
- OBERMULLER, N., UNGER, T., CULMAN, J., GOHLKE, P. & BOTTARI, S.P. (1991). Distribution of angiotensin II receptor subtypes in rat brain nuclei. *Neurosci. Lett.*, **132**, 11–15.
- OLIVEIRA, D.R., SANTOS, R.A., SANTOS, G.F., KHOSLA, M. & CAMPAGNOLE-SANTOS, M.J. (1996). Changes in the baroreflex control of heart rate produced by central infusion of selective angiotensin antagonists in hypertensive rats. *Hypertension*, **27**, 1284–1290.
- PARK, C.G. & LEENEN, F.H. (2001). Effects of centrally administered losartan on deoxycorticosterone-salt hypertension rats. *J. Korean. Med. Sci.*, **5**, 553–557.
- PATON, J.F., BOSCAN, P., MURPHY, D. & KASPAROV, S. (2001). Unravelling mechanisms of action of angiotensin II on cardiorespiratory function using *in vivo* gene transfer. *Acta Physiol. Scand.*, **173**, 127–137.
- PATON, J.F. & KASPAROV, S. (1999). Differential effects of angiotensin II on cardiorespiratory reflexes mediated by nucleus tractus solitarius – a microinjection study in the rat. *J. Physiol.*, **521**, 213–225.
- PHILLIPS, M.I. & KIMURA, B. (1988). Brain angiotensin in the developing spontaneously hypertensive rat. *J. Hypertens.*, **6**, 607–612.
- PHILLIPS, M.I., MOHUCZY-DOMINIAK, D., COFFEY, M., GALLI, S.M., KIMURA, B., WU, P. & ZELLES, T. (1997). Prolonged reduction of high blood pressure with an *in vivo*, nonpathogenic, adeno-associated viral vector delivery of AT₁-R mRNA antisense. *Hypertension*, **29**, 374–380.
- PHILLIPS, M.I., SHEN, L., RICHARDS, E.M. & RAIZADA, M.K. (1993). Immunohistochemical mapping of angiotensin AT₁ receptors in the brain. *Regul. Pept.*, **44**, 95–107.
- PHILLIPS, M.I. & SUMNERS, C. (1998). Angiotensin II in central nervous system physiology. *Regul. Pept.*, **78**, 1–11.
- POTTS, P.D., ALLEN, A.M., HORIUCHI, J. & DAMPNEY, R.A. (2000). Does angiotensin II have a significant tonic action on cardiovascular neurons in the rostral and caudal VLM? *Am. J. Physiol.*, **279**, R1392–R1402.
- RAIZADA, M.K., LU, D., TANG, W., KURIAN, P. & SUMNERS, C. (1993). Increased angiotensin II type-1 receptor gene expression in neuronal cultures from spontaneously hypertensive rats. *Endocrinology*, **132**, 1715–1722.
- RAIZADA, M.K., LU, D., YANG, H., RICHARDS, E.M., GELBAND, C.H. & SUMNERS, C. (1999). Brain angiotensin receptor subtypes and their coupling to distinct signal transduction pathways. *Adv. Mol. Cell. Endocrinol.*, **9**, 75–101.
- RAIZADA, M.K., LU, D., YANG, H. & YU, K. (1996). AT₁-receptors and cellular actions of angiotensin II in neuronal cultures of stroke prone-spontaneously hypertensive rat brain. *Adv. Exp. Med. Biol.*, **396**, 71–78.
- RAIZADA, M.K., MUTHER, T.F. & SUMNERS, C. (1984). Increased angiotensin II receptors in neuronal cultures from hypertensive rat brain. *Am. J. Physiol.*, **247**, C364–C372.
- REAUX, A., FOURNIE-ZALUSKI, M.C. & LLOREN-CORTES, C. (2001). Angiotensin III: a central regulator of vasopressin release and blood pressure. *Trends Endocrinol. Metab.*, **12**, 157–162.
- RODRIGUEZ-CAMPOS, M., KADARIAN, C., RODANO, V., BIANCIOTTI, L., FERNANDEZ, B. & VATTA, M. (2000). AT₁ receptor and phospholipase C are involved in angiotensin III modulation of hypothalamic noradrenergic transmission. *Cell. Mol. Neurobiol.*, **20**, 747–762.
- RUIZ, P., BASSO, N., CANNATA, M.A. & TAQUINI, A.C. (1990). The rennin-angiotensin system in different stages of spontaneous hypertension in the rat (SHR). *Clin. Exp. Hypertens. A*, **12**, 63–81.
- RUMANTIR, M.S., KAYE, D.M., JENNINGS, G.L., VAZ, M., HASTINGS, J.A. & ESLER, M.D. (2000). Phenotypic evidence of faulty neuronal norepinephrine reuptake in essential hypertension. *Hypertension*, **36**, 824–829.
- SANDBERG, K., JI, H., CLARK, A.J., SHAPIRA, H. & CATT, K.J. (1992). Cloning and expression of a novel angiotensin II receptor subtype. *J. Biol. Chem.*, **267**, 9455–9458.
- SASAMURA, H., HEIN, L., KREIGER, J.E., PRATT, R.E., KOBILKA, B.K. & DZAU, V.J. (1992). Cloning, characterization, and expression of two angiotensin receptor (AT-1) isoforms from the mouse genome. *Biochem. Biophys. Res. Commun.*, **185**, 253–259.
- SAYESKI, P.P. & BERNSTEIN, K.E. (2001). Signal transduction mechanisms of the angiotensin II type AT(1)-receptor: looking beyond the heterotrimeric G protein paradigm. *J. Renin-Angiotensin-Aldosterone Syst.*, **2**, 4–10.
- SCHINKE, M., BALTATU, O., BOHM, M., PETERS, J., RASCHER, W., BRICCA, G., LIPPOLDT, A., GANTEN, D. & BADER, M. (1999). Blood pressure reduction and diabetes insipidus in transgenic rats deficient in brain angiotensinogen. *Proc. Natl. Acad. Sci.*, **96**, 3975–3980.
- SELTZER, A.M., ZORAD, S. & SAAVEDRA, J.M. (1995). Stimulation of angiotensin II AT₁ receptors in rat median eminence increases phosphoinositide hydrolysis. *Brain Res.*, **705**, 24–30.
- SENANAYAKE, P.D., MORIGUCHI, A., KUMAGAI, H., GANTEN, D., FERRARIO, C.M. & BROSNIHAN, K.B. (1994). Increased expression of angiotensin peptides in the brain of transgenic hypertensive rats. *Peptides*, **15**, 919–926.
- SEYEDABADI, M., GOODCHILD, A.K. & PILOWSKY, P.M. (2001). Differential role of kinases in brain stem of hypertensive and normotensive rats. *Hypertension*, **38**, 1087–1092.
- SHIBATA, K., KOMATSU, C., MISUMI, Y. & FURUKAWA, T. (1993). Developmental differences of angiotensinogen mRNA in the preoptic area between spontaneously hypertensive and age-matched Wistar-Kyoto rats. *Mol. Brain Res.*, **19**, 115–120.
- SINN, P.L. & SIGMUND, C.D. (2000). Identification of three human renin mRNA isoforms from alternative tissue-specific transcriptional initiation. *Physiol. Genom.*, **3**, 25–31.
- SMITH, J.K. & BARRON, K.W. (1990). GABAergic responses in ventrolateral medulla in spontaneously hypertensive rats. *Am. J. Physiol.*, **258**, R450–R456.
- SONG, K., ALLEN, A.M., PAXINOS, G. & MENDELSON, F.A.O. (1992). Mapping of angiotensin II receptor subtype heterogeneity in rat brain. *J. Comp. Neurol.*, **316**, 467–484.
- STADLER, T., VELTMAR, A., QADRI, F. & UNGER, T. (1992). Angiotensin II evokes noradrenaline release from the paraventricular nucleus in conscious rats. *Brain Res.*, **569**, 117–122.
- SUGA, T. & SUZUKI, M. (1979). Effects of angiotensin II on the medullary neurons and their sensitivity to acetylcholine and catecholamines. *Jpn. J. Pharmacol.*, **29**, 541–552.
- SUMNERS, C., FLEEGAL, M. & ZHU, M. (2002). Angiotensin AT₁ receptor signalling pathways in neurons. *Clin. Exp. Pharm. Physiol.*, **29**, 483–490.
- SUMNERS, C. & PHILLIPS, M.I. (1983). Central injection of angiotensin II alters catecholamine activity in rat brain. *Am. J. Physiol.*, **244**, R257–R263.
- SUMNERS, C., ZHU, M., GELBAND, C.H. & POSNER, P. (1996). Angiotensin II type 1 receptor modulation of neuronal K⁺ and Ca²⁺ currents: intracellular mechanisms. *Am. J. Physiol.*, **271**, C154–C163.
- SUN, C., DU, J., SUMNERS, C. & RAIZADA, M.K. (2002a). Phosphatidylinositol 3-kinase mediates enhanced chronotropic action of angiotensin II in the SHR brain neurons. *Hypertension*, abstract (In press).
- SUN, C., SUMNERS, C. & RAIZADA, M.K. (2002b). Chronotropic action of angiotensin II in neurons via protein kinase C and CaMKII. *Hypertension*, **39**, 562–566.
- SZCZEPANSKA-SADOWSKA, E., PACZWA, P., LON, S. & GANTEN, D. (1998). Increased pressor function of central vasopressinergic

- system in hypertensive renin transgenic rats. *J. Hypertens.*, **16**, 1505–1514.
- TAGAWA, T., FONTES, M.A.P., POTTS, P.D., ALLEN, A.M. & DAMPNEY, R.A.L. (2000). The physiological role of AT₁ receptors in the ventrolateral medulla. *Braz. J. Med. Biol. Res.*, **33**, 643–652.
- TAGAWA, T., HORIUCHI, J., POTTS, P.D. & DAMPNEY, R.A.L. (1999). Sympathoinhibition after angiotensin receptor blockade in the rostral ventrolateral medulla is independent of glutamate and GABA receptors. *J. Auton. Nerv. Syst.*, **77**, 21–30.
- TAKEDA, K. & BUNAG, R.D. (1980). Augmented sympathetic nerve activity and pressor responsiveness in DOCA hypertensive rats. *Hypertension*, **2**, 97–101.
- TAKEDA, K., NAKATA, T., TAKESAKO, T., ITOH, H., HIRATA, M., KAWASAKI, S., HAYASHI, J., OGURO, M., SASAKI, S. & NAKAGAWA, M. (1991). Sympathetic inhibition and attenuation of spontaneous hypertension by PVN lesions in rats. *Brain Res.*, **543**, 296–300.
- TAMURA, K., UMEMURA, S., NYUI, N., YAMAKAWA, T., YAMAGUCHI, S., ISHIGAMI, T., TANAKA, S., TANIMOTO, K., TAKAGI, N., SEKIHARA, H., MURAKAMI, K. & ISHII, M. (1996). Tissue-specific regulation of angiotensinogen gene expression in spontaneously hypertensive rats. *Hypertension*, **27**, 1216–1223.
- TASKER, J.G. & DUDEK, F.E. (1991). Electrophysiological properties of neurones in the region of the paraventricular nucleus in slices of rat hypothalamus. *J. Physiol.*, **434**, 271–293.
- TERUYA, H., MURATANI, H., TAKISHITA, S., SESOKO, S., MATAYOSHI, R. & FUKIYAMA, K. (1995). Brain angiotensin II contributes to the development of hypertension in Dahl–Iwai salt-sensitive rats. *J. Hypertens.*, **13**, 883–890.
- TOUYZ, R.M. & SCHIFFRIN, E.L. (2000). Signal transduction mechanisms mediating the physiological and pathophysiological actions of angiotensin II in vascular smooth muscle cells. *Pharmacol. Rev.*, **52**, 639–672.
- TSUTSUMI, K. & SAVEEDRA, J.M. (1991). Characterization and development of angiotensin II receptor subtypes (AT₁ and AT₂) in rat brain. *Am. J. Physiol.*, **216**, R209–R216.
- VEERASINGHAM, S.J., YANG, H., FRANCIS, S.C., SUMNERS, C. & RAIZADA, M.K. (2002). Profiling reveals altered Angiotensin II regulation of gene expression in neurons from pre-hypertensive SHR. *Hypertension*, abstract (In press).
- VELTMAR, A., CULMAN, J., QADRI, F., RASCHER, W. & UNGER, T. (1992). Involvement of adrenergic and angiotensinergic receptors in the paraventricular nucleus in the angiotensin II-induced vasopressin release. *J. Pharmacol. Exp. Ther.*, **263**, 1253–1260.
- WANG, D., SUMNERS, C., POSNER, P. & GELBAND, C.H. (1997). A-type K⁺ current in neurons cultured from neonatal rat hypothalamus and brain stem: modulation by angiotensin II. *J. Neurophysiol.*, **78**, 1021–1029.
- WEYHENMEYER, J.A. & PHILLIPS, M.I. (1982). Angiotensin-like immunoreactivity in the brain of the spontaneously hypertensive rat. *Hypertension*, **4**, 514–523.
- WIELBO, D., SERNIA, C., GYURKO, R. & PHILLIPS, M.I. (1995). Antisense inhibition of hypertension in the spontaneously hypertensive rat. *Hypertension*, **25**, 314–319.
- WRIGHT, J.W., SULLIVAN, M.J., QUIRK, W.S., BATT, C.M. & HARDING, J.W. (1987). Heightened blood pressure and drinking responsiveness to intracerebroventricularly applied angiotensins in the spontaneously hypertensive rat. *Brain Res.*, **420**, 289–294.
- YANG, C.R., PHILLIPS, M.I. & RENAUD, L.P. (1992a). Angiotensin II receptor activation depolarizes rat supraoptic neurons *in vitro*. *Am. J. Physiol.*, **263**, R1333–R1338.
- YANG, H., FRANCIS, S.C., SELLERS, K., DEBARROS, M., SUN, C., SUMNERS, C., FERRARIO, C.M., KATOVITCH, M.J., MURO, A.F. & RAIZADA, M.K. (2002). Hypertension-linked decrease in the expression of brain γ -adducin. *Circ. Res.*, **91**, 633–639.
- YANG, H., LU, D. & RAIZADA, M.K. (1997a). Angiotensin II-induced phosphorylation of the AT₁ receptor from rat brain neurons. *Hypertension*, **30**, 351–357.
- YANG, H., LU, D., YU, K. & RAIZADA, M.K. (1996). Regulation of neuromodulatory actions of angiotensin II in the brain neurons by the Ras-dependent mitogen activated protein kinase pathway. *J. Neurosci.*, **16**, 4047–4058.
- YANG, H. & RAIZADA, M.K. (1998). MAP kinase-independent signaling in angiotensin II regulation of neuromodulation in SHR neurons. *Hypertension*, **32**, 473–481.
- YANG, H. & RAIZADA, M.K. (1999). Role of phosphatidylinositol 3-kinase in angiotensin II regulation of norepinephrine neuromodulation in brain neurons of the spontaneously hypertensive rat. *J. Neurosci.*, **19**, 2413–2423.
- YANG, H., WANG, X. & RAIZADA, M.K. (2001). Characterization of signal transduction pathway in neurotropic action of Angiotensin II in brain neurons. *Endocrinology*, **142**, 3502–3511.
- YANG, R.H., JIN, H., WYSS, J.M. & OPARIL, S. (1992). Depressor effect of blocking angiotensin subtype 1 receptors in anterior hypothalamus. *Hypertension*, **19**, 475–481.
- YANG, S.N., LIPPOLDT, A., JANSSON, A., PHILLIPS, M.I., GANTEN, D. & FUXE, K. (1997). Localization of angiotensin II AT₁ receptor-like immunoreactivity in catecholaminergic neurons of the rat medulla oblongata. *Neuroscience*, **81**, 503–515.
- YU, K., LU, D., ROWLAND, N.E. & RAIZADA, M.K. (1996). Angiotensin II regulation of tyrosine hydroxylase gene expression in the neuronal cultures of normotensive and spontaneously hypertensive rats. *Endocrinology*, **137**, 3566–3576.
- ZHU, D.N., MORIGUCHI, A., MIKAMI, H., HIGAKI, J. & OGIHARA, T. (1998). Central amino acids mediate cardiovascular response to angiotensin II in the rat. *Brain Res. Bull.*, **45**, 189–197.
- ZHU, M., GELBAND, C.H., POSNER, P. & SUMNERS, C. (1999). Angiotensin II decreases neuronal delayed rectifier potassium current: role of calcium/calmodulin-dependent protein kinase II. *J. Neurophysiol.*, **82**, 1560–1568.
- ZINI, S., FOURNIE-ZALUSKI, M.C., CHAUVEL, E., ROQUES, B.P., CORVOL, P. & LLORENS-CORTES, C. (1996). Identification of metabolic pathways of brain angiotensin II and III using specific aminopeptidase inhibitors: predominant role of angiotensin III in the control of vasopressin release. *Proc. Natl. Acad. Sci.*, **93**, 11968–11973.

(Received February 18, 2003)

Accepted February 27, 2003)